David Elkins Sells 30,000 Shares of Bristol Myers Squibb (NYSE:BMY) Stock

Bristol Myers Squibb Company (NYSE:BMY) EVP David Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bristol Myers Squibb Price Performance

Shares of BMY traded down $2.16 during mid-day trading on Thursday, reaching $59.57. 13,517,905 shares of the stock traded hands, compared to its average volume of 13,503,015. The company has a market cap of $121.63 billion, a price-to-earnings ratio of 17.27, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm has a fifty day moving average price of $59.18 and a 200 day moving average price of $52.52. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter last year, the business posted $1.67 EPS. The company’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Morgan Stanley reissued an “underweight” rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a report on Friday, February 6th. HSBC raised their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price for the company. Finally, UBS Group reissued a “buy” rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $61.41.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase‑3 data from the SCOUT‑HCM trial for Camzyos — the results (including adolescents) raise the drug’s commercial and label‑expansion potential, which could add meaningful future product revenue if regulators and payers align. BMY Announces Positive Data from the Phase 3 SCOUT‑HCM Trial of Camzyos
• Positive Sentiment: Surge in call‑option activity (≈66,895 calls, +81% vs. avg) — elevated bullish options flow suggests some traders are positioning for upside from catalysts (trial/regulatory updates or broader biotech lift).
• Neutral Sentiment: Janux Therapeutics nominated a development candidate under its BMS collaboration, which triggered a $35M milestone payment to Janux — indicates active external R&D partnering but represents routine collaboration mechanics. Janux Announces Development Candidate; $35M Milestone
• Neutral Sentiment: Market opportunity writeups (HNSCC and RCC market reports) highlight large addressable markets where BMY competes — useful long‑term context but not an immediate stock mover. HNSCC Market Projected Growth
• Neutral Sentiment: Analyst/features pieces raising attention to BMY’s earnings history and investor interest — suggests increased eyes on upcoming catalysts (earnings, regulatory updates).
• Negative Sentiment: Insider sale: EVP David V. Elkins sold 30,000 shares at ~$61.67 (≈$1.85M) and trimmed his holdings ~15.8% — a large, disclosed insider sell can weigh on sentiment even if sales are for diversification. SEC Form 4 — David V. Elkins Sale
• Negative Sentiment: Recent quarterly results (Feb 5) included an EPS miss vs. estimates and conservative FY‑2026 EPS guidance (6.05–6.35), which remains a backdrop for investor skepticism until BMY shows consistent upside to consensus.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BMY. Vanguard Group Inc. grew its holdings in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares during the last quarter. State Street Corp lifted its stake in Bristol Myers Squibb by 1.4% in the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after purchasing an additional 1,385,206 shares during the last quarter. Geode Capital Management LLC boosted its position in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after buying an additional 6,084,046 shares during the period. Norges Bank purchased a new stake in Bristol Myers Squibb during the fourth quarter valued at about $1,947,272,000. Finally, Ameriprise Financial Inc. grew its stake in shares of Bristol Myers Squibb by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock valued at $1,508,099,000 after buying an additional 432,158 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.